Melvin Rothberg is Director at Lotus Pharmaceuticals, Inc. (LTUS). They have made 1 open-market trade across 1 company since 2008, most recently 2008-01-02.
CIK 0001180623
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| LTUS | 30,000 | — |
Shares reported on the most recent Form 4, priced at the 2008-01-09 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LTUS | SELL | 2008-01-02 | 2008-01-09 | $1.01 | $30K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.